FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).

NCT ID: NCT01332526

Last Updated: 2011-04-18

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 70 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-05-31

Brief Summary

Fructose intake from added sugars has increased dramatically over the last century and has recently been implicated as potential contributor to metabolic syndrome, obesity, hypertension, inflammation and kidney disease. Fructose differs from the other sugars because, uric acid is generated during its metabolism. Serum uric acid levels have been found to correlate with the intake of fructose and added sugars. In turn, an elevated serum uric acid has also been shown to be associated with increased risk for cardiovascular and metabolic diseases. On the other hand complexity of fructose metabolism in each individuals results of the various magnitude of hyperuricemia induced by fructose intake. The magnitude of uric acid production in each patient may reflect individual predisposition to endogenous urate production in a face of relatively normal fasting uric acid concentration. Therefore the oral fructose tolerance test might reveal an occult purine disturbances which plays casual role in either metabolic disturbances or organ damage.

The aim of this study is to see whether is a relationship between fructose induced hyperuricemia and metabolic disturbances , inflammatory state and organ damage in obese and various stages CKD patients.

Detailed Description

The study will be performed in two experimental groups. Proposed study groups Study I Patients with BMI> 30 and metabolic syndrome. Patient with BMI> 30 without metabolic syndrome. Normal healthy controls. Study II Patients with CKD stage III and uric acid < 7 mg/dl Patients with CKD stage III and uric acid > 7 mg/dl Patient with asymptomatic hyperuricemia and eGFR > 90 ml/min/1.73 m2, , uric acid > 7 mg/dl Hemodialysis patients

Characteristics of the particular patients group- including criteria:

10- 15 participants in each subset of each group age 18-65 y. Gender: females and males in equal proportion. Group I Patients with BMI> 30 and metabolic syndrome ( ATP III). Patient with BMI> 30 without metabolic syndrome. Normal healthy control- healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).

Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

• without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg) Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl
• without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.

• CKD: nondiabetic nephropathy
• duration hemodialysis 3-48 months
• Hb-11-13 g/dl
• well controlled hypertension ( < 140/90 mmHg)
• without ACEi, ARB, allopurinol treatment
• residual diuresis will be estimated for last 48 hours-between mid and next dialysis Method of investigation All patients and controls ( but hemodialysis) will present after overnight fast. Baseline tests include 24 hr urine collection for: sodium, calcium, phosphorus, creatinine, uric acid, NAG, albumin will be carry out and the same morning fasting sample of blood for: creatinine, cystatin C , uric acid, sodium, glucose, insulin, triglycerides, HDL and LDL cholesterol, calcium, phosphorus, hsCRP. BP will be determined as the mean of three readings taken 5 min apart while sitting. Next in all patients and controls fructose tolerance test will be performed. The test consists of giving 1 gram/kg b.w. of fructose p.o. with blood collection at 0,30,60 and 120 min afterward for serum uric acid determination and uric acid area under the curve will be calculated. The calculated area under curve is the measure of occult uric acid disturbance when compared to controls.

Day before the urine collection the ABPM , BMI, IM (intima media ratio) , renal duplex ultrasound (RI) will be done

Measure BMI, waist circumference

Conditions

Obesity; Chronic Kidney Disease; Metabolic Syndrome

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients with BMI> 30 and metabolic syndrome ( ATP III).

Patients with BMI\> 30 and metabolic syndrome ( ATP III).

No interventions assigned to this group

Patient with BMI> 30 without metabolic syndrome.

Patient with BMI\> 30 without metabolic syndrome.

No interventions assigned to this group

Normal healthy control

healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI \< 25;normotensives ).

No interventions assigned to this group

Patients with CKD stage III and uric acid < 7 mg/dl

Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

• without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

No interventions assigned to this group

Patients with CKD stage III and uric acid > 7 mg/dl

Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl

• without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

No interventions assigned to this group

Patient with asymptomatic hyperuricemia

Patient with asymptomatic hyperuricemia, uric acid \> 7 mg/dl with normal renal function

No interventions assigned to this group

Hemodialysis patients

Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.

• CKD: nondiabetic nephropathy
• duration hemodialysis 3-48 months
• Hb-11-13 g/dl
• well controlled hypertension ( < 140/90 mmHg)
• without ACEi, ARB, allopurinol treatment
• residual diuresis will be estimated for last 48 hours-between mid and next dialysis

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Group I Patients with BMI> 30 and metabolic syndrome ( ATP III). Patient with BMI> 30 without metabolic syndrome. Normal healthy control- healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).

Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

• without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg) Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl
• without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.

• CKD: nondiabetic nephropathy
• duration hemodialysis 3-48 months
• Hb-11-13 g/dl
• well controlled hypertension ( < 140/90 mmHg)
• without ACEi, ARB, allopurinol treatment
• residual diuresis will be estimated for last 48 hours-between mid and next dialysis

Exclusion Criteria

• immunosuppressive agents, ACEi, ARB, allopurinol treatment
• diabetes mellitus
• not well controlled hypertension ( > 140/90 mmHg)
• proteinuria > 3,5 g/24 h

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Colorado, Denver

OTHER

Sponsor Role: collaborator

Collegium Medicum w Bydgoszczy

OTHER

Sponsor Role: lead

Responsible Party

Chief, Division of Renal Diseases and Hypertension

Principal Investigators

Jacek JM Manitius

Role: STUDY_CHAIR

Department of Nephrology, Hypertension and Internal Diseases Nicolaus Copernicus University in Torun Poland Collegium Medicum in Bydgoszcz

Central Contacts

Jacek JM Manitius

Role: CONTACT

nerka@nerkacpro.pl

+48525854030

References

Donderski R, Miskowiec-Wisniewska I, Kretowicz M, Grajewska M, Manitius J, Kaminska A, Junik R, Siodmiak J, Stefanska A, Odrowaz-Sypniewska G, Pluta A, Lanaspa M, Johnson RJ. The fructose tolerance test in patients with chronic kidney disease and metabolic syndrome in comparison to healthy controls. BMC Nephrol. 2015 May 3;16:68. doi: 10.1186/s12882-015-0048-y.

Reference Type: DERIVED

PMID: 25935771 (View on PubMed)

Other Identifiers

FFT Bydgoszcz

Identifier Type: -

Identifier Source: org_study_id